Sonny Hsiao, Acepodia CEO

Ace­po­di­a's off-the-shelf cell ther­a­pies get an­oth­er $100M for on­col­o­gy tri­als

Cal­i­for­nia and Taipei biotech Ace­po­dia has lined up an­oth­er six-fig­ure fund­ing round to take its off-the-shelf cell ther­a­pies for­ward.

Spun out of No­bel lau­re­ate Car­olyn Bertozzi’s lab and found­ed in 2017 by ex-Juno EVP Patrick Yang and UC Berke­ley cell bi­ol­o­gist Son­ny Hsiao, the biotech has now raised a to­tal of $259 mil­lion thanks to a $100 mil­lion Se­ries D dis­closed Tues­day morn­ing.

The round fol­lows a $109 mil­lion Se­ries C in De­cem­ber 2021, at which point Yang told End­points News the start­up would mon­i­tor the pub­lic mar­kets and con­sid­er whether to go pub­lic in 2022. But as the mar­kets cooled fol­low­ing a pan­dem­ic high, the biotech chose to go with an­oth­er pri­vate round, led by Dig­i­tal Mo­bile Ven­ture, to bankroll clin­i­cal tri­als of al­lo­gene­ic cell ther­a­pies in non-Hodgkin lym­phoma and EGFR-ex­press­ing sol­id tu­mors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.